 TRACON Pharmaceuticals NASDAQ:TCON Inc said it has ended its third quarter 2021 with cash and equivalents of 29.9 million as of September 30, 2021, as the company expects to file an investigational new drug application IND and initiate a Phase 12 trial of YH001 combined with envafolimab in soft tissue sarcoma subtypes in early 2022. TRACON also noted it anticipates initiating trials of YH001 in other indications in combination with approved standard of care agents in late 2022. 